Navigation Links
U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014
Date:9/1/2010

INDIANAPOLIS, Sept. 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.

"We are pleased with today's ruling from the Court of Appeals regarding Evista's method-of-use patents and believe that the Court fairly applied long-standing patent law principles," said Robert A. Armitage, senior vice president and general counsel for Lilly.  "We remain confident that Evista's method-of-use patents are valid, a conclusion reached by both the District Court and now the Court of Appeals. Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. We will continue to vigorously defend our rights, in order to support the development of the next generation of innovative medicines."

The Court of Appeals also affirmed a prior District Court ruling that held Evista's particle-size patents invalid. The company will review its legal options regarding this aspect of the ruling.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Evista patent litigation. These statements are based on management's current expectations but actual results may differ materially.  There can be no assurance that the company will prevail in any further appeal. Other risk factors that may affect the company's results can be found in the company's latest Form 10-K, filed February 2010, and Form 10-Q, filed July 2010.

Evista® (raloxifene HCl, Lilly)

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
2. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
3. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
4. Montana Supreme Court Decision Endangers Most Vulnerable Citizens
5. U.S. Court of Appeals Upholds AstraZeneca AWP Settlement
6. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
7. CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures
8. Texas Court Asked to Appoint Receiver for Key Subsidiary of TSX Listed Northstar Healthcare, Inc. (TSX NHC) on Claims of Mismanagement and Breach of Fiduciary Duty
9. Watson Says Appeals Court Affirms Concerta(R) Patent Invalid
10. Appellate Court Decides in Favor of Fenwal
11. CRESTOR® Patent Upheld By US Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Newly published research from the CVS Health (NYSE: ... private retailer can play in restricting access to tobacco ... in the American Journal of Public Health , ... all CVS Pharmacy stores reduced the number of cigarette ... impact on those who bought cigarettes exclusively at CVS ...
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, Inc. ... company focused on the development and commercialization of ... pain, announced that Vincent J. Angotti ... member of the company,s board of directors, effective ... two decades of experience leading executive and commercial ...
(Date:2/16/2017)... , Feb. 16, 2017  Prescription pain medications provided ... visit are necessary for long-term opioid use to take ... 16 th edition of The New England ... physicians see more patients in acute pain than in ... , MD, FACEP, president of the American College of ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a national staffing ... named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , ... notable contributions to the staffing industry over the last twelve months. Industry insiders ...
(Date:2/17/2017)... CO (PRWEB) , ... February 17, 2017 , ... Top ... annual International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, ... Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 ...
(Date:2/16/2017)... York, New York (PRWEB) , ... February 17, ... ... work and determination. After what took over 10 years of research, development and ... technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ingredients ...
(Date:2/16/2017)... ... February 17, 2017 , ... The Price Agency, a ... and entrepreneurs in the Birmingham area, is announcing an ongoing charity event to ... her medically challenged son, Anius. , Anius is medically complex with diagnoses consisting ...
Breaking Medicine News(10 mins):